We additionally found CD4+ T cell helper epitopes to be equally effective in supporting Cltc-specific CD8+ T cell responses in vaccines formulated as completely tumor-specific (contained within the same or distinct NeoAg) or tumor-nonspecific (application of a universal helper epitope), suggesting that tumor-specific endogenous effector functions of CD4+ T cells (Figure 1D) might be dispensable in our model during therapeutic vaccination. The gene discussed is CD4; the disease is neoplasm.